GlassScriptPhysician profile
Ramchand B Ranai
NPI 1083604003
$813.61
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $186 · 2021: $129.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $242.99 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $168.53 | 2019-2020 | |
| Covidien LP | $54.95 | 2019-2020 | |
| Vifor Pharma, INC. | $47.14 | 2019 | |
| Horizon Therapeutics Plc | $44.85 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $43.89 | 2019 | |
| Fresenius USA Marketing, INC. | $31.59 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $22.06 | 2019 | |
| Glaxosmithkline, LLC. | $21.91 | 2021 | |
| Akebia Therapeutics INC | $19.70 | 2020 | |
| Travere Therapeutics, INC. | $17.50 | 2019 | |
| Genentech USA, INC. | $17.27 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $16.28 | 2019 | |
| Bard Peripheral Vascular, INC. | $14.94 | 2019 | |
| Genzyme Corporation | $13.58 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $12.52 | 2021 | |
| Mallinckrodt Hospital Products INC. | $12.19 | 2020 | |
| Opko Pharmaceuticals, LLC | $11.72 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramchand Ranai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.